Trial reportNutrition, metabolism, and cardiovascular diseases : NMCD2020
Soy food intake associates with changes in the metabolome and reduced blood pressure in a gut microbiota dependent manner.
Trial report in Nutrition, metabolism, and cardiovascular diseases : NMCD, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02010359 (Omega-3 PUFA Suppress Adipochemokines), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Omega-3 PUFA Suppress Adipochemokines
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- Impact of Plant-Based Drinks on Cardiometabolic Outcomes: A Systematic Review and Network Meta-analysis.Advances in nutrition (Bethesda, Md.) · 2026Pooled it
- A metabolome and microbiome wide association study of healthy eating index points to the mechanisms linking dietary pattern and metabolic status.European journal of nutrition · 2021Pooled it
- Soy and the gut microbiome: a bi-directional relationship shaping nutrition and health.European journal of nutrition · 2026Review
- Impact of Culinary Treatments on the Immunoreactivity of Soy Protein Isolates.Foods (Basel, Switzerland) · 2025Article
- The gut-heart axis: a correlation between Paneth cells' dysfunction, microbiome dysbiosis, and cardiovascular diseases.Cell communication and signaling : CCS · 2025Review
- A Review of Bioactive Compound Effects from Primary Legume Protein Sources in Human and Animal Health.Current issues in molecular biology · 2024Review
- Advances in Gut Microbiota-Targeted Therapeutics for Metabolic Syndrome.Microorganisms · 2024Review
- Role of gut microbiota in cardiovascular diseases - a comprehensive review.Annals of medicine and surgery (2012) · 2024Review
- Gut microbiota as a residual risk factor causally influencing cardiac structure and function: Mendelian randomization analysis and biological annotation.Frontiers in microbiology · 2024Article
- Pharmacological and Nutritional Modulation of Metabolome and Metagenome in Cardiometabolic Disorders.Biomolecules · 2023Review
- Gut Microbiota and Microbial Metabolism in Early Risk of Cardiometabolic Disease.Circulation research · 2023Review
- Combating hypertension beyond genome-wide association studies: Microbiome and artificial intelligence as opportunities for precision medicine.Cambridge prisms. Precision medicine · 2023Review
- New hope for Parkinson's disease treatment: Targeting gut microbiota.CNS neuroscience & therapeutics · 2022Review
- Review
- Intestinal Flora: A Potential New Regulator of Cardiovascular Disease.Aging and disease · 2022Review
- Plasma Metabolite Profiles Following Consumption of Animal Protein and Soybean-Based Diet in Hypercholesterolemic Postmenopausal Women.Metabolites · 2022Article
- Genistein-Opportunities Related to an Interesting Molecule of Natural Origin.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
aimsConsumption of soy foods has been associated with protection against cardiometabolic disease, but the mechanisms are incompletely understood. We hypothesized that habitual soy food consumption associates with gut microbiome composition, metabolite production, and the interaction between diet, microbiota and metabolites. METHODS AND
resultsWe analyzed dietary soy intake, plasma and stool metabolites, and gut microbiome data from two independent cross-sectional samples of healthy US individuals (N = 75 lean or overweight, and N = 29 obese). Habitual soy intake associated with several circulating metabolites. There was a significant interaction between soy intake and gut microbiome composition, as defined by gut enterotype, on metabolites in plasma and stool. Soy consumption associated with reduced systolic blood pressure, but only in a subset of individuals defined by their gut microbiome enterotype, suggesting that responsiveness to soy may be dependent on microbiome composition. Soy intake was associated with differences in specific microbial taxa, including two taxa mapping to genus Dialister and Prevotella which appeared to be suppressed by high soy intake We identified context-dependent effects of these taxa, where presence of Prevotella was associated with higher blood pressure and a worse cardiometabolic profile, but only in the absence of Dialister.
conclusionsThe gut microbiome is an important intermediate in the interplay between dietary soy intake and systemic metabolism. Consumption of soy foods may shape the microbiome by suppressing specific taxa, and may protect against hypertension only in individuals with soy-responsive microbiota. CLINICAL TRIALS REGISTRY: NCT02010359 at clinicaltrials.gov.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.